Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Altor_BioScience
|
| gptkbp:alternativeName |
gptkb:ImmunityBio,_Inc.
|
| gptkbp:CEO |
gptkb:Patrick_Soon-Shiong
|
| gptkbp:collaboratesWith |
gptkb:NantKwest
|
| gptkbp:developedBy |
cell-based therapies
immuno-oncology products |
| gptkbp:focusesOn |
gptkb:cancer
immunotherapy T-cell therapy natural killer cell therapy |
| gptkbp:foundedBy |
gptkb:Patrick_Soon-Shiong
|
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:Culver_City,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NantCell
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:parentCompany |
gptkb:NantWorks
|
| gptkbp:publiclyTraded |
gptkb:NASDAQ:_IBRX
|
| gptkbp:website |
https://www.nantcell.com/
|
| gptkbp:bfsParent |
gptkb:NantWorks
|
| gptkbp:bfsLayer |
6
|